Massachusetts Financial Services Co. MA increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 54.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 7,731 shares of the biopharmaceutical company’s stock after purchasing an additional 2,728 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in Gilead Sciences were worth $597,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of GILD. Penn Davis Mcfarland Inc. lifted its holdings in Gilead Sciences by 0.5% in the 3rd quarter. Penn Davis Mcfarland Inc. now owns 179,737 shares of the biopharmaceutical company’s stock valued at $13,877,000 after acquiring an additional 887 shares during the last quarter. Dearborn Partners LLC lifted its holdings in Gilead Sciences by 37.8% in the 3rd quarter. Dearborn Partners LLC now owns 259,206 shares of the biopharmaceutical company’s stock valued at $20,014,000 after acquiring an additional 71,145 shares during the last quarter. ST Germain D J Co. Inc. lifted its holdings in Gilead Sciences by 47.8% in the 3rd quarter. ST Germain D J Co. Inc. now owns 5,767 shares of the biopharmaceutical company’s stock valued at $445,000 after acquiring an additional 1,866 shares during the last quarter. GW Henssler & Associates Ltd. lifted its holdings in Gilead Sciences by 1.3% in the 3rd quarter. GW Henssler & Associates Ltd. now owns 177,874 shares of the biopharmaceutical company’s stock valued at $13,734,000 after acquiring an additional 2,301 shares during the last quarter. Finally, Handelsbanken Fonder AB lifted its holdings in Gilead Sciences by 32.1% in the 3rd quarter. Handelsbanken Fonder AB now owns 323,570 shares of the biopharmaceutical company’s stock valued at $24,983,000 after acquiring an additional 78,700 shares during the last quarter. 78.09% of the stock is owned by institutional investors and hedge funds.

A number of brokerages have weighed in on GILD. BidaskClub raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a report on Thursday. Mizuho set a $94.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a report on Friday, October 26th. Barclays upped their price target on shares of Gilead Sciences from $90.00 to $95.00 and gave the company an “overweight” rating in a report on Friday, October 26th. Evercore ISI reissued a “buy” rating on shares of Gilead Sciences in a report on Wednesday, October 31st. Finally, Robert W. Baird downgraded shares of Gilead Sciences from an “outperform” rating to a “neutral” rating and set a $79.00 price target for the company. in a report on Thursday, July 26th. Twelve research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $87.84.

In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $78.04, for a total transaction of $3,902,000.00. Following the completion of the sale, the director now directly owns 3,067,762 shares of the company’s stock, valued at $239,408,146.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold 150,000 shares of company stock valued at $11,087,500 over the last ninety days. Insiders own 1.30% of the company’s stock.

GILD stock opened at $71.18 on Friday. The company has a quick ratio of 3.39, a current ratio of 3.45 and a debt-to-equity ratio of 1.09. Gilead Sciences, Inc. has a one year low of $64.27 and a one year high of $89.54. The stock has a market cap of $93.76 billion, a price-to-earnings ratio of 11.29, a PEG ratio of -2.81 and a beta of 1.01.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.84 EPS for the quarter, beating analysts’ consensus estimates of $1.63 by $0.21. Gilead Sciences had a net margin of 7.12% and a return on equity of 39.32%. The company had revenue of $5.60 billion during the quarter, compared to analyst estimates of $5.44 billion. During the same period in the prior year, the firm earned $2.27 earnings per share. Sell-side analysts predict that Gilead Sciences, Inc. will post 6.44 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 28th. Shareholders of record on Friday, December 14th will be paid a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a yield of 3.20%. The ex-dividend date is Thursday, December 13th. Gilead Sciences’s dividend payout ratio is presently 26.64%.

TRADEMARK VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) Shares Bought by Massachusetts Financial Services Co. MA” was originally reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.dailypolitical.com/2018/11/10/gilead-sciences-inc-gild-shares-bought-by-massachusetts-financial-services-co-ma.html.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Featured Story: How analysts view the yield curve

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.